Functionally, genetic knockdown of FGFR1 or pharmacological targeting with erdafitinib, a selective small molecule targeting FGFRs, induced cell cycle arrest, cell death in-vitro, reduced tumor formation, and improved overall survival in-vivo. This evidence concerns the gene FGFR1 and neoplasm.